What Moved Markets This Week
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
seekingalpha.com
prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney’s lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy. react™ has received regenerative medicine advanced therapy (rmat) designation, as well as fda and ema guidance, supporting its ongoing phase 3 clinical program, which launched in january 2022. for more information, visit www.prokidney.com.
| Year | Revenue Est. | Rev Growth | EPS Est. | Analysts |
|---|---|---|---|---|
| FY2027 | $299167 | — | -$0.69 | Moderate4 |
| FY2028 | $58.0M | ▲ +19284.1% | -$0.39 | High5 |
| FY2029 | $128.6M | ▲ +121.8% | -$0.26 | Low2 |
prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.